Friday, January 21, 2022

Longeveron Inc. (LGVN) stock sky rocketed during after-hours. Here’s to why?

Longeveron Inc. (NASDAQ: LGVN) stock gained by 135.27% at last close however its hiked by 50.95% in the after-hours trading session, as well. Longeveron is a clinical-stage biotechnology business focused on creating cellular therapeutics for age-related and life-threatening diseases.


3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free.

Sponsored


LGVN stock’ Significant Update

The FDA has given Lomecel-B RPD designation for the cure of Hypoplastic Left Heart Syndrome (HLHS), a severe and life-threatening congenital heart condition in neonates, according to Longeveron. In a Phase 2 trial, Lomecel-B, an experimental allogeneic bone marrow-derived medical signalling cell (MSC) product, is being examined.


A Backdoor Way To Profit From Today’s Crypto Bull Market

Even if you’re not actively in crypto, you deserve to know what’s actually going on...

Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.

Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free. .

Sponsored


Every year, about 1,000 babies in the United States are delivered with HLHS. The left ventricle of HLHS new-borns is underdeveloped, impairing the heart’s ability to pump blood to the whole body. Without surgical treatment, HLHS is frequently fatal. Three surgical procedures are conducted over a 5-year period to enable the right ventricle to be designed to pump blood to the body. Longeveron is testing the safety of injecting Lomecel-B into the right ventricle during the second operation (4–6 months of age), as well as the influence on heart function and other health outcomes.

Also,

Longeveron recently released the findings of their Lomecel-B safety-focused Phase I clinical research in HLHS participants. The cells were well accepted when cardiologists administered Lomecel-B directly into the newborns’ hearts during surgery, with no severe negative cardiac events or infections linked to the exploratory treatment.

Between 2 and 3.5 years after surgery, 100% of the infants who participated in the Phase 1 trial (n=10) were living and had not needed a transplant. Other health indicators, such as weight gain and growth patterns, were comparable to that of healthy babies.

Moreover,

The FDA may give RPD status to disorders that mainly affect children aged 18 and under and impact fewer than 200,000 people in the United States. If the FDA approves Lomecel-B for the cure of HLHS, Longeveron may also be qualified for a priority review voucher (PRV). It can happen if the application for the medicine meets specific criteria and is approved by September 30, 2026, as required by existing law.

Latest news

Here’s the Reason of Sonoma Pharmaceuticals, Inc. (SNOA) Stock Gaining Momentum in Aftermarket.

Sonoma Pharmaceuticals, Inc. (SNOA) is an innovative and leading global brand engaged in the development of stabilized hypochlorous acid products for different applications including...

Looking Under The Hood: What’s Happening To Bee Vectoring Technologies (BEVVF) Stock

Bee Vectoring Technologies International Inc (BEVVF) closed up 24.71 percent on Wednesday at $0.3280, and has been trading in a day range of $0.2721...

Best cannabis stock investment could lead to great profits in the near future

In recent months, there has been much debate about which are the best cannabis stocks. There are several states where recreational marijuana is legal,...

Stealth BioTherapeutics Inc. (MITO) stock rose during after-hours, provided no current update.

Stealth BioTherapeutics Inc. (NASDAQ: MITO) stock plunged by 3.57% at last close whereas the MITO stock price gains by 6.17% in the after-hour trading...

Related news

Here’s the Reason of Sonoma Pharmaceuticals, Inc. (SNOA) Stock Gaining Momentum in Aftermarket.

Sonoma Pharmaceuticals, Inc. (SNOA) is an innovative and leading global brand engaged in the development of stabilized hypochlorous acid products for different applications including...

Looking Under The Hood: What’s Happening To Bee Vectoring Technologies (BEVVF) Stock

Bee Vectoring Technologies International Inc (BEVVF) closed up 24.71 percent on Wednesday at $0.3280, and has been trading in a day range of $0.2721...

Best cannabis stock investment could lead to great profits in the near future

In recent months, there has been much debate about which are the best cannabis stocks. There are several states where recreational marijuana is legal,...

Stealth BioTherapeutics Inc. (MITO) stock rose during after-hours, provided no current update.

Stealth BioTherapeutics Inc. (NASDAQ: MITO) stock plunged by 3.57% at last close whereas the MITO stock price gains by 6.17% in the after-hour trading...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

1745

SPECIAL GIFT

WE HAVE A GIFT FOR YOU

Download Free eBook For

7 GROWTH STOCKS FOR 2021

100% free. stop anytime no spam